MA56029A - Molécules de liaison au tigit et pd-1/tigit - Google Patents

Molécules de liaison au tigit et pd-1/tigit

Info

Publication number: MA56029A
Authority: MA; Morocco
Prior art keywords: tigit; binding molecules; tigit binding; molecules; binding
Prior art date: 2019-05-29

Application number

MA056029A

Other languages

English (en)

Inventor

Yiqing Feng

Naresh Kumar

James David Pancook

Stephanie Marie Truhlar

Yang Zhao

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-05-29

Filing date

2020-05-22

Publication date

2022-04-06

2020-05-22 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2022-04-06 Publication of MA56029A publication Critical patent/MA56029A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MA056029A 2019-05-29 2020-05-22 Molécules de liaison au tigit et pd-1/tigit MA56029A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201962853816P	2019-05-29	2019-05-29

Publications (1)

Publication Number	Publication Date
MA56029A true MA56029A (fr)	2022-04-06

Family

ID=71070067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA056029A MA56029A (fr)	2019-05-29	2020-05-22	Molécules de liaison au tigit et pd-1/tigit

Country Status (24)

Country	Link
US (1)	US20220227860A1 (fr)
EP (1)	EP3976652A1 (fr)
JP (2)	JP7241207B2 (fr)
KR (1)	KR20220004120A (fr)
CN (1)	CN113939536B (fr)
AR (1)	AR118980A1 (fr)
AU (1)	AU2020283817A1 (fr)
BR (1)	BR112021021795A2 (fr)
CA (1)	CA3139025A1 (fr)
CL (1)	CL2021003039A1 (fr)
CO (1)	CO2021015610A2 (fr)
CR (1)	CR20210573A (fr)
DO (1)	DOP2021000241A (fr)
EA (1)	EA202192796A1 (fr)
EC (1)	ECSP21085693A (fr)
IL (1)	IL287765A (fr)
JO (1)	JOP20210314A1 (fr)
MA (1)	MA56029A (fr)
MX (1)	MX2021014472A (fr)
PE (1)	PE20220505A1 (fr)
PH (1)	PH12021552970A1 (fr)
SG (1)	SG11202112725XA (fr)
TW (1)	TWI760751B (fr)
WO (1)	WO2020242919A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20230937T1 (hr)	2017-01-05	2023-11-24	Kahr Medical Ltd.	Pd1-41bbl fuzijski protein i metode korištenja istog
WO2018127916A1 (fr)	2017-01-05	2018-07-12	Kahr Medical Ltd.	Protéine de fusion pd1-cd70 et ses procédés d'utilisation
PT3565828T (pt)	2017-01-05	2022-02-08	Kahr Medical Ltd	Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
SG11202013170RA (en)	2018-07-11	2021-01-28	Kahr Medical Ltd	Pd1-4-1bbl variant fusion protein and methods of use thereof
KR20210044220A (ko)	2018-07-11	2021-04-22	카 메디컬 리미티드	SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
TW202216778A (zh)	2020-07-15	2022-05-01	美商安進公司	Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20240076346A1 (en) *	2021-01-13	2024-03-07	Kahr Medical Ltd.	Type i membrane proteins heterodimers and methods of use thereof
US11939382B2 (en) *	2021-04-30	2024-03-26	Medimmune, Llc	Bispecific PD-1 and TIGIT binding proteins and uses thereof
TW202304965A (zh)	2021-05-04	2023-02-01	美商艾吉納斯公司	抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
TW202327610A (zh) *	2021-08-30	2023-07-16	美商G1治療公司	具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療
TW202337897A (zh) *	2021-11-18	2023-10-01	大陸商信達生物製藥（蘇州）有限公司	抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法
US20250179176A1 (en)	2022-05-02	2025-06-05	Arcus Biosciences, Inc.	Anti-tigit antibodies and uses of the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2014290069B2 (en) *	2013-07-16	2019-01-03	Genentech, Inc.	Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
JP2017522311A (ja)	2014-07-16	2017-08-10	ジェネンテック，インコーポレイテッド	Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法
MY198017A (en)	2014-08-19	2023-07-26	Merck Sharp & Dohme	Anti-tigit antibodies
AR103268A1 (es)	2014-12-23	2017-04-26	Bristol Myers Squibb Co	Anticuerpos contra tigit
TWI715587B (zh)	2015-05-28	2021-01-11	美商安可美德藥物股份有限公司	Ｔｉｇｉｔ結合劑和彼之用途
KR20250021613A (ko)	2015-09-25	2025-02-13	제넨테크, 인크.	항-tigit 항체 및 이의 이용 방법
CN112274637A (zh)	2016-08-17	2021-01-29	康姆普根有限公司	抗tigit抗体、抗pvrig抗体及其组合
JOP20190133A1 (ar) *	2016-12-08	2019-06-02	Innovent Biologics Suzhou Co Ltd	أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CN109071656B (zh) *	2017-01-05	2021-05-18	璟尚生物制药公司	检查点调节物拮抗剂
US11021537B2 (en) *	2017-05-01	2021-06-01	Agenus Inc.	Anti-TIGIT antibodies and methods of use thereof
AR112603A1 (es) *	2017-07-10	2019-11-20	Lilly Co Eli	Anticuerpos biespecíficos inhibidores de punto de control
IL272227B2 (en) *	2017-07-27	2025-09-01	iTeos Belgium SA	Anti-tigit antibodies
AU2018396970B2 (en) *	2017-12-28	2025-09-25	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against TIGIT
EP3813864A4 (fr) *	2018-06-29	2022-07-20	Gensun Biopharma Inc.	Antagonistes antitumoraux

2020
- 2020-05-19 TW TW109116479A patent/TWI760751B/zh not_active IP Right Cessation
- 2020-05-21 AR ARP200101441A patent/AR118980A1/es not_active Application Discontinuation
- 2020-05-22 CN CN202080039788.0A patent/CN113939536B/zh active Active
- 2020-05-22 MX MX2021014472A patent/MX2021014472A/es unknown
- 2020-05-22 SG SG11202112725XA patent/SG11202112725XA/en unknown
- 2020-05-22 PH PH1/2021/552970A patent/PH12021552970A1/en unknown
- 2020-05-22 EA EA202192796A patent/EA202192796A1/ru unknown
- 2020-05-22 US US17/613,675 patent/US20220227860A1/en not_active Abandoned
- 2020-05-22 EP EP20731763.7A patent/EP3976652A1/fr active Pending
- 2020-05-22 KR KR1020217038318A patent/KR20220004120A/ko not_active Withdrawn
- 2020-05-22 JO JOP/2021/0314A patent/JOP20210314A1/ar unknown
- 2020-05-22 PE PE2021001860A patent/PE20220505A1/es unknown
- 2020-05-22 AU AU2020283817A patent/AU2020283817A1/en not_active Abandoned
- 2020-05-22 JP JP2021569860A patent/JP7241207B2/ja active Active
- 2020-05-22 BR BR112021021795A patent/BR112021021795A2/pt not_active IP Right Cessation
- 2020-05-22 MA MA056029A patent/MA56029A/fr unknown
- 2020-05-22 CR CR20210573A patent/CR20210573A/es unknown
- 2020-05-22 CA CA3139025A patent/CA3139025A1/fr active Pending
- 2020-05-22 WO PCT/US2020/034158 patent/WO2020242919A1/fr not_active Ceased
2021
- 2021-11-01 IL IL287765A patent/IL287765A/en unknown
- 2021-11-17 CL CL2021003039A patent/CL2021003039A1/es unknown
- 2021-11-22 CO CONC2021/0015610A patent/CO2021015610A2/es unknown
- 2021-11-25 DO DO2021000241A patent/DOP2021000241A/es unknown
- 2021-11-26 EC ECSENADI202185693A patent/ECSP21085693A/es unknown
2023
- 2023-03-06 JP JP2023033480A patent/JP2023071889A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DOP2021000241A (es)	2021-12-30
CN113939536A (zh)	2022-01-14
WO2020242919A1 (fr)	2020-12-03
TWI760751B (zh)	2022-04-11
US20220227860A1 (en)	2022-07-21
BR112021021795A2 (pt)	2022-01-04
JP2023071889A (ja)	2023-05-23
PE20220505A1 (es)	2022-04-07
MX2021014472A (es)	2022-01-06
JP2022533457A (ja)	2022-07-22
KR20220004120A (ko)	2022-01-11
AU2020283817A1 (en)	2021-11-25
CO2021015610A2 (es)	2021-11-30
TW202110884A (zh)	2021-03-16
CN113939536B (zh)	2024-05-14
EA202192796A1 (ru)	2022-03-03
CL2021003039A1 (es)	2022-08-05
SG11202112725XA (en)	2021-12-30
JP7241207B2 (ja)	2023-03-16
PH12021552970A1 (en)	2022-07-25
JOP20210314A1 (ar)	2023-01-30
EP3976652A1 (fr)	2022-04-06
CA3139025A1 (fr)	2020-12-03
ECSP21085693A (es)	2021-12-30
IL287765A (en)	2022-01-01
CR20210573A (es)	2021-12-15
AR118980A1 (es)	2021-11-17

Publication	Publication Date	Title
MA56029A (fr)	2022-04-06	Molécules de liaison au tigit et pd-1/tigit
IL280004A (en)	2021-03-01	Antibody molecules that bind pd-l1 and cd137
EP3802581A4 (fr)	2022-04-13	Protéines de liaison multispécifiques et améliorations de celles-ci
EP3891181A4 (fr)	2022-08-17	Molécules de liaison à cd3 et leurs utilisations
IL285502A (en)	2021-09-30	Binding proteins specific for ras neoantigens and uses thereof
EP4013792A4 (fr)	2023-10-04	Molécules de liaison multimériques immunostimulatrices
IL287479A (en)	2021-12-01	Cd19 binding molecules and uses thereof
GB202109794D0 (en)	2021-08-18	Anti-TCR antibody molecules and uses thereof
EP3538150A4 (fr)	2020-07-08	Molécules de liaison spécifiques d'asct2 et leurs utilisations
EP3355920A4 (fr)	2019-05-15	Protéines de liaison à pd-1 et leurs méthodes d'utilisation
DK3472207T3 (da)	2021-04-12	Bindingsmolekyler, der binder pd-l1 og lag-3
GB2598218B (en)	2024-05-08	Anti-TCR antibody molecules and uses thereof
EP3997230A4 (fr)	2023-08-02	Molécules de liaison à la claudine-6 et leurs utilisations
MA44885A (fr)	2019-03-13	Protéines de liaison bispécifiques et leurs utilisations
EP3442592A4 (fr)	2019-11-27	Conjugués de liaison au récepteur de la neurotensine et formulations associées
EP3613772A4 (fr)	2020-12-30	Molécule de liaison spécifique pour la protéine lrig-1 et son utilisation
EP4013796A4 (fr)	2023-08-02	Molécules de liaison anti-cd123 bispécifiques multimères et leurs utilisations
EP3917542A4 (fr)	2023-03-08	Protéines de liaison multispécifiques
EP3781202A4 (fr)	2022-01-05	Anticorps de liaison au pd-1 et leurs utilisations
EP3781204A4 (fr)	2022-03-30	Molécules de liaison
EP3794039A4 (fr)	2022-05-04	Anticorps de liaison à pd-1 et utilisation associée
EP3426680A4 (fr)	2020-03-11	Protéines de liaison au récepteur de l'activine de type 2 et leurs utilisations
KR20220016865A9 (ko)	2022-02-21	항원 결합 분자, 약학 조성물, 및 방법
IL286013A (en)	2021-10-31	Cd3 binding molecules
EP3774922A4 (fr)	2022-01-05	Molécules de liaison impliquant des cellules